Department of Health and Human Services April 15, 2005 – Federal Register Recent Federal Regulation Documents

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), announces that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in 1. E-223- 1992/0-US-01, ``SIGNAL TRANSDUCTION INHIBITOR COMPOUNDS'', by Elise Kohn, Lance Liotta, Christian Felder, issued Pat No. 5,359,078 (issue date October 25, 1994); 2. E-223-1992/0-US-02, ``SIGNAL TRANSDUCTION INHIBITOR TRIAZOLE AND DIAZOLE COMPOUNDS'' by Elise Kohn, Lance Liotta, Christian Felder, issued Pat No. 5,482,954 (issue date January 9, 1996); 3. E-223-1992/0-US-03, ``SIGNAL TRANSDUCTION INHIBITOR 1,2,3,- TRIAZOLO COMPOUNDS'' by Elise Kohn, Lance Liotta, Christian Felder, issued Pat No. 5,498,620, (issued date March 12, 1996); 4. E-223-1992/ 0-US-04, ``SIGNAL TRANSDUCTION INHIBITOR COMPOUNDS'' by Elise Kohn, Lance Liotta, Christian Felder, issued Pat No 5,705,514 (issued date January 6, 1998); 5. E-223-1992/0-US-05, ``SIGNAL TRANSDUCTION INHIBITOR COMPOUNDS'' by Elise Kohn, Lance Liotta, Christian Felder, issued Pat No 5,880,129 (issued date March 9, 1999); 6. E-068-1991/1- US-01, ``METHOD FOR INHIBITING METALLOPROTEINASE EXPRESSION'' by Elise Kohn, Lance Liotta, issued Pat No. Pat No. 5,602,156 (issued date February 11, 1997); 7. E-220-1993/1-US-01 ``METHOD FOR INHIBITING ANGIOGENESIS'' by Elise Kohn, Lance Liotta and Riccardo Alessandro issued patent No 5,744,492 (issue date April 28,1998), to RFE Pharma, having a place of business in Framingham, MA. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to therapeutics for the treatment of retinopathy.